drugset / Trial / NCT04712357

Clinical Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19

NCT04712357

RandomizedParallel-groupDouble-blindTreatment

Summary

Clinical, control, double-blind, randomized trial with tenofovir disoproxyl fumarate and emtricitabine for Covid-19

Timeline

Start
2020-11-09
Primary completion
2022-01
Completion
2023-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tenofovir disoproxyl fumarate Unknown 300 mg Oral
Comparator emtricitabine Other / unclassified 200 mg Oral

Indications